Dissimilar teen crash rates in two neighboring southeastern Virginia cities with different high school start times.

STUDY OBJECTIVES: Early high school start times may contribute to insufficient sleep leading to increased teen crash rate. Virginia Beach (VB) and Chesapeake are adjacent, demographically similar cities. VB high schools start 75-80 minutes earlier than Chesapeake's. We hypothesized that VB teens would manifest a higher crash rate than Chesapeake teens. METHODS: The Virginia Department of Motor Vehicles (DMV) provided de-identified, aggregate 2008 and 2007 data for weekday crashes and crash times in VB and Chesapeake for drivers aged 16-18 years ("teens"), and provided 2008 and 2007 crash data for all drivers. Data allowed comparisons of VB versus Chesapeake crash rates for teens (overall and hour-by-hour), and teens versus all other ages. We compared AM and PM traffic congestion (peak hours) in the two cities. RESULTS: In 2008, there were 12,916 and 8,459 Virginia Beach and Chesapeake 16- to 18-year-old drivers, respectively. For VB and Chesapeake, teen drivers' crash rates in 2008 were 65.8/1000 and 46.6/1000 (p < 0.001), respectively, and in 2007 were 71.2/1000 and 55.6/1000. Teen drivers' crash peaks in the morning occurred one hour earlier in VB than Chesapeake, consistent with school commute time. Congestion data for VB and Chesapeake did not explain the different crash rates. CONCLUSIONS: A significantly increased teen crash rate for both 2008 and 2007 occurred in VB, the city with earlier high school start times. Future studies using individual level data may clarify if sleep restriction, circadian dyssynchrony, and sleep inertia might contribute to this increased crash rate.

Pediatric sleep pharmacology.

This article reviews the most common pharmacologic options in the treatment of sleep disorders in children. Despite the high prevalence of sleep disorders in children, there is a paucity of education and information available on the pharmacologic management of sleep disorders in children. The principles of sleep physiology and pathophysiology that help provide more rational pharmacologic management are discussed. Medications are typically not Food and Drug Administration (FDA) approved for the pediatric age range or for the specific sleep disorder. Medications have a role for insomnia, narcolepsy, parasomnias, and sleep-related movement disorders. The available choices of hypnotics are reviewed. Medications to increase alertness of narcoleptics and decrease cataplexy are discussed. The use of dopaminergic agents for Restless Legs Syndrome is reviewed. The potential use of medication in sleep apnea is also reviewed. Pharmacologic guidelines need to be developed specifically for sleep disorders in children. Ideally, these guidelines should be FDA approved for the specific sleep disorder and for the pediatric age range. The development of easy to swallow, chewable or liquid forms of these medications are needed. Training programs should play the lead role in enhancing pediatricians' knowledge of the pharmacologic treatment of sleep disorders in children.